Incyte's CEO Hervé Hoppenot Steps Down, Raising M&A Prospects
Company - People | Jun 26, 2025 | EIN
Incyte's longtime CEO Hervé Hoppenot is stepping down after transforming the biotechnology company over his 11-year tenure. Under his leadership, Incyte expanded its product line from one to multiple therapies, achieving revenues of $4.2 billion in the last year, with quarterly earnings surpassing $1 billion by Q4 2023. Bill Meury, a seasoned biopharma executive with a track record in mergers and acquisitions, is set to succeed Hoppenot. His appointment points to potential M&A activity, given his previous roles in significant company transitions. Meury's arrival comes as Incyte plans to leverage its robust internal R&D pipeline and navigate the approaching patent expiration of its flagship product, Jakafi, by focusing on other rising therapies. His strategic priorities include accelerating product development and sustaining growth, with a target of launching 10 new products by 2030, starting with several anticipated in 2025.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- United States – Incyte is an American biopharmaceutical company based in the US, impacting the local and global drug market.
Industry
- Biotechnology – As a company focused on drug development and innovative therapies, Incyte operates within the biotechnology industry.
- Pharmaceuticals – Incyte's portfolio, which includes commercial drugs like Jakafi and Opzelura, situates it in the pharmaceuticals sector.
- Healthcare – Incyte is part of the broader healthcare sector, developing treatments for complex health issues.
Financials
- 4.2 billion – Incyte's revenue in the previous year.
- 2.92 billion to 2.97 billion – Forecasted sales for Jakafi in 2025.
- 630 million to 670 million – Expected sales for Opzelura in 2025.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Incyte Corporation | Target Company | Company | Incyte Corporation is a US-based biopharmaceutical company involved in drug development for serious diseases. |
| Hervé Hoppenot | Outgoing CEO | Person | Hervé Hoppenot was the CEO of Incyte for over a decade, overseeing significant growth in the company's revenue and product portfolio. |
| Bill Meury | Incoming CEO | Person | Bill Meury is a biopharma veteran with a history in M&A activities, now appointed CEO of Incyte. |
| Novartis | Former Company of Hervé Hoppenot and Bill Meury | Company | Novartis is a global healthcare company engaged in drug development and commercial operations. |
| Anthos Therapeutics | Former Company of Bill Meury | Company | Anthos Therapeutics, previously led by Bill Meury, was acquired by Novartis. |
| Karuna Therapeutics | Former Company of Bill Meury | Company | Bill Meury headed Karuna Therapeutics before its merger with Bristol Myers Squibb. |